|
|
|
|
Vol. 11, No. 23,
pp. 3157-3167,
December 1, 1997
-inducible transcriptional complexes
Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 USA
| |
Abstract |
|---|
|
|
|---|
Upon ligand binding, the receptors of the TGF
family
phosphorylate Smad proteins, which then move into the nucleus where they activate transcription. To carry out this function, the
receptor-activated Smads 1 and 2 require association with the product
of deleted in pancreatic carcinoma, locus 4 (DPC4),
Smad4. We investigated the step at which Smad4 is required for
transcriptional activation. Smad4 is not required for nuclear
translocation of Smads 1 or 2, or for association of Smad2 with a DNA
binding partner, the winged helix protein FAST-1. Receptor-activated
Smad2 takes Smad4 into the nucleus where they form a complex with
FAST-1 that requires these three components to activate transcription.
Smad4 contributes two functions: Through its amino-terminal domain,
Smad4 promotes binding of the
Smad2/Smad4/FAST-1 complex to DNA; through
its carboxy-terminal domain, Smad4 provides an activation function required for Smad1 or Smad2 to stimulate transcription. The dual function of Smad4 in transcriptional activation underscores its central
role in TGF
signaling.
[Key Words:
TGF
; activin; BMP; SMAD; signal
transduction; transcriptional regulation; tumor suppressors]
| |
Introduction |
|---|
|
|
|---|
The transformation growth factor
(TGF
)
family signals a wide variety of biological responses
through transcriptional regulation of genes encoding critical
determinants of cell fate such as cell-cycle regulators (Pietenpol et
al. 1990
; Hannon and Beach 1994
; Datto et al. 1995
; Reynisdóttir
et al. 1995
; Iavarone and Massagué 1997
), differentiation factors
(Zentella and Massagué 1992
), extracellular matrix proteins (Kerr
et al. 1988
; Rossi et al. 1988
; Keeton et al. 1991
; Inagaki et al.
1994
) or homeobox gene products (Huang et al. 1995
). Clues about the
mechanism of transcriptional regulation by the TGF
family have
been provided by the recent discovery of the SMAD proteins as direct
substrates of TGF
family receptors and mediators of receptor
signals to the nucleus. The founding member of the SMAD family is the
product of the Drosophila gene Mad, which was
identified as being required for signaling by the BMP homolog
Decapentaplegic (Dpp) (Sekelsky et al. 1995
). The discovery of Mad and
the identification of nematode and vertebrate Mad-related gene products
termed SMADs allowed the elucidation of a signaling pathway in which
receptor phosphorylated SMADs move into the nucleus to activate
transcription (for review, see Derynck and Zhang 1996
; Wrana and
Attisano 1996
; Massagué et al. 1997
).
The members of the SMAD family contain highly conserved amino- and
carboxy-terminal domains (referred to as N and C domains, or MH1 and
MH2 domains, respectively), separated by a more divergent linker
region. On the basis of structural and functional criteria, the SMAD
family can be divided into three subgroups. One group includes those
SMADs that are direct receptor substrates. The second group includes
co-SMADs, or SMADs that are not direct receptor substrates, but
participate in signaling by associating with receptor-activated SMADs
(for review, see Derynck and Zhang 1996
; Wrana and Attisano 1996
;
Massagué et al. 1997
). The third group includes proteins that
interfere with SMAD activation and can be referred to as anti-SMADs
(Hayashi et al. 1997
; Topper et al. 1997
).
Among the receptor-regulated SMADs, Smad1 and presumably its close
homologs Smad5 and Smad9 are bone morphogenetic protein (BMP) receptor
substrates and mediators of BMP signals in vertebrates (Graff et al.
1996
; Hoodless et al. 1996
; Lechleider et al. 1996
; Liu et al. 1996
;
Thomsen 1996
; Yingling et al. 1996
; Kretzschmar et al. 1997a
; Watanabe
et al. 1997
), whereas Mad in Drosophila (Newfeld et al. 1996
;
Wiersdorff et al. 1996
) and Sma-2 and Sma-3 in Caenorhabditis
elegans (Savage et al. 1996
) mediate the actions of BMP-like
factors in these organisms. Smad2 and Smad3 are substrates and
mediators of related TGF
and activin receptors in vertebrates (Baker and Harland 1996
; Eppert et al. 1996
; Graff et al. 1996
; Macias-Silva et al. 1996
; Zhang et al. 1996
). Receptor-regulated SMADs
are phosphorylated by the receptors at the carboxy-terminal end, which
typically is an SSV/MS sequence
(Macias-Silva et al. 1996
; Kretzschmar et al. 1997a
). The N and C
domains of these SMADs interact with each other, causing auto
inhibition (Baker and Harland 1996
; Liu et al. 1996
; Hata et al. 1997
),
and agonist-induced phosphorylation may relieve this inhibition.
On phosphorylation of the carboxy-terminal residues, SMADs move into
the nucleus (Hoodless et al. 1996
; Liu et al. 1996
; Nakao et al.
1997
a,b) where they participate in agonist-dependent transcriptional activation as originally inferred from studies showing that Smad1 fused
to the GAL4 DNA-binding domain has transcriptional activity that is
regulated by BMP (Liu et al. 1996
). As further evidence for a direct
role of SMADs in transcription, activin has been shown to activate the
Mix.2 homeobox gene in Xenopus by inducing the
association of Smad2 with FAST-1 (Chen et al. 1996
), a nuclear protein
that belongs to the winged helix transcription factor family and
recognizes an activin responsive element (ARE) in the Mix.2
promoter (Huang et al. 1995
). This has led to a model in which
receptor-activated Smad2 translocates into the nucleus where it
associates with a DNA-binding protein forming a transcriptional complex
(Chen et al. 1996
).
Signaling by receptor-regulated SMADs requires the participation of a
co-SMAD. The only known member of this group in vertebrates is Smad4.
Smad4 has the same overall structure as the receptor-regulated SMADs,
but is more divergent and lacks the carboxy-terminal phosphorylation motif. Smad4 was originally identified as the product of the
DPC4 tumor suppressor (Hahn et al. 1996
) that is mutated or
deleted in a high proportion of pancreatic cancers and in a smaller
proportion of other cancers (Barrett et al. 1996
; Hahn et al. 1996
; Kim
et al. 1996
; Nagatake et al. 1996
; Schutte et al. 1996
). Inactivating missense mutations have been found both in the N and C domains in
different tumor-derived DPC4 alleles. A similar distribution of inactivating mutations has been observed in another tumor suppressor in this family, Smad2 (Eppert et al. 1996
; Riggins et al.
1996
; Uchida et al. 1996
). The C domain of SMADs has effector function in various biological assays (Baker and Harland 1996
; Lagna et al.
1996
; Liu et al. 1996
) and mutations in this domain disrupt its
activity (Shi et al. 1997
). The crystal structure of the Smad4 C domain
reveals that it is a trimer, and certain mutations disrupt the monomer
interfaces of this trimer (Shi et al. 1997
). Mutations in the N domain
of Smad2 and Smad4 augment the autoinhibitory function of this domain
(Hata et al. 1997
) and may have additional effects (Kim et al. 1997
).
A general requirement of Smad4 in TGF
family signaling is
suggested not only by the requirement of Smad4 for TGF
responsiveness in mammalian cells (Lagna et al. 1996
; Zhang et al.
1996
) but also by its requirement for activin and BMP responses in
Xenopus embryo (Lagna et al. 1996
, Zhang et al. 1997
). Thus,
Smad4 is a shared co-Smad, participating in both
TGF
/activin and BMP signaling pathways. Smad4
associates with Smad1 or Smad2 when these SMADs are phosphorylated by
specific receptors (Lagna et al. 1996
) and is required for their
signaling function (Lagna et al. 1996
; Zhang et al. 1996
, 1997
). The
interaction between the receptor-regulated SMADs and Smad4 is mediated
by their C domains (Hata et al. 1997
; Wu et al. 1997
).
Although Smad4 is recognized as a central mediator for TGF
signaling, it was not clear which step of the SMAD-signaling pathway requires Smad4 function. In this study we made use of a Smad4-deficient cell line and the FAST-1/Mix.2 system
reconstituted in mammalian cells to investigate this problem. We show
that Smad4 is not required for nuclear translocation of a
receptor-activated SMAD but its association with a receptor-activated
SMAD promotes binding of the SMAD complex to DNA and, furthermore, it
provides an essential transcriptional activation function.
| |
Results |
|---|
|
|
|---|
Nuclear translocation of Smad1 and Smad2 does not require Smad4
To investigate which step of the TGF
and BMP signaling
pathways requires Smad4, we first determined whether ligand-dependent nuclear translocation of Smad1 and Smad2 can occur in the absence of
Smad4. When expressed as amino-terminal epitope-tagged constructs in
SW480.7 human colon carcinoma cells (Goyette et al. 1992
), which lack
Smad4 (Zhang et al. 1996
), Smad1 and Smad2 were mostly cytoplasmic
under basal conditions (Fig. 1A). Upon cotransfection with constitutively active BMP or TGF
receptors and treatment with
BMP4 or TGF
, respectively, Smad1 or Smad2 accumulated in the
nucleus (Fig. 1A). No further increases in the nuclear localization of
Smad1 or Smad2 were detected on cotransfection of Smad4 (data not
shown). These results indicate that Smad4 is not required for nuclear
translocation of Smad1 or Smad2.
|
Smad4 nuclear translocation depends on receptor activated SMADs
Transfected Smad4 is localized predominantly in the cytoplasm in
SW480.7 cells (Fig. 1B) or COS cells (data not shown), as visualized by
immunostaining via an amino-terminal Flag epitope tag. The nuclear
level of Flag-Smad4 was increased only slightly by BMP4 (Fig. 1C).
Cotransfection with Smad1 or Smad2 had little effect on the cellular
localization of Flag-Smad4 (Fig. 1C). Cotransfection of Smad1 or Smad2
(or Smad3, which is expressed at a higher level than Smad2 under these
conditions), however, enabled Flag-Smad4 to accumulate in the nucleus
in response to BMP4 or TGF
, respectively (Fig. 1B,C). In the
absence of cotransfected Smad1, Smad2, or Smad3, the endogenous level
of these proteins in SW480.7 cells may be too low to carry a detectable
proportion of the overexpressed Smad4 into the nucleus in response to
ligand. Because agonist-induced activation of Smad1 and Smad2 leads to
their association with Smad4 (Lagna et al. 1996
; Kretzschmar et al.
1997a
), we surmise that the activated Smads bind Smad4 in the cytoplasm
and carry it into the nucleus.
Reconstitution of a Xenopus
activin/TGF
transcriptional response in
mammalian cells
To investigate whether Smad4 might be essential for the formation
of a transcriptional complex, we first reconstituted, in mammalian
cells, the FAST-1-dependent transcriptional response from
Xenopus, which is the only example to date of a natural
transcriptional complex formed in response to a TGF
family member
and involving SMADs. Activin signaling in Xenopus early
embryos induces the formation of an activin response factor (ARF) that
contains Smad2 and FAST-1 (Chen et al. 1996
), binds to the activin
response element ARE in the Mix.2 promoter, and activates the
reporter construct A3CAT that contains three copies of the ARE (Huang
et al. 1995
). As shown in Figure 2, A3CAT responded
to activin when cotransfected with FAST-1 but not when transfected
alone into the lung epithelial cell line R1B/L17. This
response was not increased when the activin type I receptor ActR-IA was
overexpressed. Overexpression of ActR-IB caused a high basal activation
of A3CAT (Fig. 2), suggesting that ActR-IB can mediate this response.
Because the ActR-IB kinase domain shares 97% sequence similarity with
that of the TGF
type I receptor T
R-I (Cárcamo et al.
1994
), we tested whether A3CAT could be activated via T
R-I.
R-1B/L17 cells, which lack T
R-I but become
responsive to TGF
on transfection of this receptor (Wrana et al.
1994
; Weis-Garcia and Massagué 1996
), showed a FAST-1- and
T
R-I-dependent activation of A3CAT by TGF
(Fig. 2). In a
recent study, Hayashi et al. (1997)
have also shown that the A3CAT
reporter gene can be activated by TGF
. Because of the limited
availability of activin, the remaining work was carried out by use of
TGF
as the agonist.
|
C domains mediate the Smad2/FAST-1 interaction
The presence of both Smad2 and FAST-1 in Xenopus ARF has
been inferred from gel shift assays by use of the ARE probe (Chen et
al. 1996
). Consistent with the gel shift result, we were able to detect
a TGF
-induced Smad2-FAST-1 association in R-1B/L17 cells by coimmunoprecipitation assay (Fig. 3A). The
interaction is specific because TGF
did not induce association of
Smad1 with FAST-1 (data not shown). The C domain in Smad2 has effector
activity that is inhibited by the N domain (Baker and Harland 1996
; Liu et al. 1996
; Hata et al. 1997
). Receptor-mediated phosphorylation relieves this repression and additionally enhances the signaling function of the isolated C domain (Hata et al. 1997
). In agreement with
this, the isolated C domain of Smad2 interacted constitutively, albeit
weakly, with FAST-1, and this interaction was increased by TGF
addition (Fig. 3A). Mutation of the receptor phosphorylation sites at
the carboxyl terminus of Smad2 (Macias-Silva et al. 1996
; Kretzschmar
et al. 1997a
) prevented the binding to FAST-1 (Fig. 3A, AAMA
construct). A Smad2 nonsense mutant lacking the entire phosphorylation
region [Smad2(1-429)] and a phosphorylation-defective mutant
[Smad2(D450E) (Eppert et al. 1996
)] were also unable to associate
with FAST-1 (Fig. 3A). The various constructs were controlled to be
expressed at comparable levels (data not shown). To map the binding
region on FAST-1, we constructed a panel of Myc epitope-tagged FAST-1
deletion mutants (Fig. 3B), and found that Smad2 associates with the C
domain but not the DNA-binding domain of FAST-1 (Fig. 3C). Thus, Smad2
can associate with FAST-1 in mammalian cells in an agonist-dependent
and specific manner, and this interaction is mediated via the C domains
of the two proteins.
|
The Smad2/FAST-1 interaction does not require Smad4
To determine whether FAST-1 and Smad2 can interact with each other
in a Smad4-independent manner, we analyzed the association of Smad2 and
FAST-1 in SW480.7 cells. As shown in Figure 4A,
TGF
induced the formation of the Smad2/FAST-1
complex in SW480.7 cells. The FAST-1 and Smad2 complex was unaffected
when Smad4 was cotransfected (Fig. 4A). We also observed an interaction
between Smad2 and FAST-1 in the yeast two-hybrid system and in vitro
(data not shown). This indicates that the interaction between Smad2 and
FAST-1 is direct and does not require Smad4.
|
Smad4 forms a ternary complex with Smad2 and FAST-1
In contrast to Smad2, Smad4 did not form a stable complex with
FAST-1 when cotransfected as epitope-tagged constructs in SW480.7 cells
(Fig. 4B). TGF
induced the association of Smad4 and FAST-1, however, when these constructs were cotransfected with Smad2 (Fig. 4B).
To determine whether Smad2, Smad4, and FAST-1 are in the same complex,
COS cells were cotransfected with Flag-tagged Smad2, HA-tagged Smad4,
and Myc-tagged FAST-1. Cell lysates were immunoprecipitated with Flag
antibody coupled to agarose beads. Immune complexes were eluted with
Flag peptide and the eluate used in a second immunoprecipitation with
Myc antibody. Finally, the precipitate was analyzed by immunoblotting
with HA antibody. As shown in Figure 4C, a ternary complex was detected
when cells were cotransfected with all three constructs and incubated
with TGF
, but not when any one construct was omitted or when
TGF
was not added. Furthermore, the TGF
-induced association
of Smad2 and Smad4 (Fig. 4D) was strongly enhanced when these
constructs were cotransfected with FAST-1 (Fig. 4D). Similar results
were obtained in R-1B/L17 cells (data not shown). FAST-1
therefore appears to stabilize the Smad2-Smad4 interaction.
Smad4 promotes DNA binding and transcriptional activation by the ternary complex
To determine whether Smad4 is required for the formation of a
TGF
-inducible DNA-protein complex, we assayed SW480.7 cell extracts for TGF
-inducible binding activity by use of the ARE oligonucleotide probe. Nuclear extracts from cells transfected with
FAST-1 alone yielded a small amount of Myc-FAST-1-ARE complex, which
comigrated with a background band but was revealed by supershift with
anti-Myc antibody (Fig. 5A; data not shown).
Importantly, no TGF
-inducible ARE-binding complex was detected in
cells transfected with vector alone or FAST-1 alone, or Smad2 and Smad4
(Fig. 5A, lanes 1-6). Although FAST-1 and Smad2 can form a stable
complex as shown in the coimmunoprecipitation assay (Figs. 3A and 4A), little or no new ARE-binding complex was observed when Smad2 was cotransfected with FAST-1 in these cells (Fig. 5A, lanes 7,8). Cotransfection of Smad4 with FAST-1 yielded limited levels of binding
(lanes 9,10). FAST-1, Smad2, and Smad4 transfected together, however,
yielded a high basal level of binding activity that was further
increased by TGF
(lanes 11,12). We also performed the same
experiment with whole cell extracts. In agreement with a previous
report (Chen et al. 1996
), whole cell extracts from cells transfected
with FAST-1 alone yield high levels of FAST-1-ARE complex (data not
shown). Smad4 as well as Smad2, however, were required for formation of
a TGF
-inducible ARE-binding complex (data not shown), in agreement
with the results by use of nuclear extracts.
|
The ability of Smad4 to associate with Smad2 and FAST-1 in response to
TGF
and the requirement of Smad4 for the generation of an
ARE-binding complex correlated with an essential role of Smad4 in
trancriptional activation of the A3CAT reporter gene (Fig. 5B).
Cotransfection of FAST-1 and Smad2 led to a very low level of
activation of the A3CAT reporter gene in the presence of TGF
in
SW480.7 cells. Transcriptional activation of the A3CAT reporter gene
occurred when Smad-4 and FAST-1 were cotransfected (Fig. 5B), which is
consistent with the notion that these cells contain low level of
endogenous Smad2-like activity. Cotransfection of Smad2, Smad4, and
FAST-1 together led to a strong basal activation of A3CAT that was
further increased by TGF
addition (Fig. 5B).
To establish that Myc-FAST-1, Flag-Smad2, and Smad4-HA are all in the same ARE-binding complex, we used antibodies against the epitope tags of each of these constructs to supershift the complex (Fig. 5C, lanes 7-9). Combinations of any two or all three antibodies yielded supershifts of progressively lower electrophoretic mobility (Fig. 5C, lanes 10-13). The Flag antibody did not lead to any detectable supershift in nuclear or whole cell extracts from cells transfected with FAST-1 and Smad2 (data not shown) further indicating that the Smad2/FAST-1 complex has little ARE-binding activity in these assays. The results indicate that the Smad2/Smad4/FAST-1 ternary complex binds DNA as one entity.
The N domain of Smad4 contributes to DNA binding
Because the isolated C domain of Smad4 can stably interact with
Smad2 (Hata et al. 1997
), we analyzed whether it can generate an
ARE-binding complex together with Smad2 and FAST-1. As shown in Figure
6A, the Smad4 C domain transfected with Smad2 and
FAST-1 led to an ARE-binding complex with 20-fold lower efficiency than the full-length Smad4. Furthermore, Smad4 constructs with partial or
complete deletion of the N domain were inefficient at supporting A3CAT
activation (Fig. 6B). Taken together, these observations imply that the
N domain of Smad4 contributes to binding of the ternary complex to the
ARE. In contrast, the N domain of Smad2 is not essential for activation
of the A3CAT reporter gene (Fig. 6B).
|
The C domain of Smad4 is required for transcriptional activation by receptor-regulated Smads
To determine whether Smad4 has additional roles in the
transcriptional complex besides promoting binding to DNA, we used a transcription assay in which Smad binding to a GAL4 reporter gene is
ensured by a DNA-binding domain of GAL4 fused amino-terminally to
Smads. In this assay, GAL4-Smad1 (Liu et al. 1996
) and GAL4-Smad2 (F. Liu et al., unpubl.) activate transcription in response to BMP and
TGF
/activin, respectively, in R1B/L17
cells that contain wild-type Smad4. To determine whether the
transcription activities of GAL4-Smad1 and GAL4-Smad2 are dependent
on Smad4, we performed the same assay in SW480.7 cells that lack
endogenous Smad4. Figure 7A shows that GAL4-Smad1
and GAL4-Smad2 had very low activity in SW480.7 cells even in the
presence of ligand stimulation, but were greatly stimulated by BMP or
TGF
when cotransfected with wild-type Smad4. Importantly, the
isolated C domain of Smad4 [Smad4(240-552) construct] was as
effective as the full-length Smad4 in restoring agonist-induced
transcriptional activation by GAL4-Smad2 (Fig. 7B) or GAL4-Smad1
(data not shown). In contrast, a Smad4 construct with a small
carboxy-terminal truncation [Smad4(1-514)] was unable to rescue
these responses (Fig. 7B). Taken together, these results indicated that
the transcriptional activity of Smad1 and Smad2 is dependent on Smad4,
and the C domain of Smad4 provides this activity.
|
| |
Discussion |
|---|
|
|
|---|
Previous work has shown that receptor-activated SMADs
move to the nucleus to activate transcription (Chen et al. 1996
;
Hoodless et al. 1996
; Liu et al. 1996
; Nakao et al. 1997
a,b), and their signaling function somehow requires Smad4 (Lagna et al. 1996
; Zhang et
al. 1996
, 1997
) with which the receptor-activated SMADs form a complex
(Lagna et al. 1996
). By examining the requirement of Smad4 in three
basic steps of the SMAD pathway, namely, nuclear translocation, binding
to DNA, and transcriptional activation, the present study sheds light
into the role of Smad4 in this process. The evidence presented here
suggests that Smad4 is dispensable for nuclear translocation of
receptor-activated SMADs, but it plays a role in their binding to DNA
and is essential for their ability to activate transcription.
Nuclear translocation of Smad4 by receptor-activated SMADs
Translocation of receptor-regulated SMADs into the nucleus is a
highly controlled process. Phosphorylation of Smad1 at carboxy-terminal sites by the BMP receptor (Kretzschmar et al. 1997a
) and
phosphorylation of Smad2 at similar sites by the TGF
receptor
(Macias-Silva et al. 1996
) mediate translocation of these SMADs into
the nucleus, whereas phosphorylation of Smad1 by mitogen-activated
protein (MAP) kinase in response to mitogenic factors inhibits nuclear translocation (Kretzschmar et al. 1997b
). Phosphorylation by TGF
family receptors also endows SMADs with the ability to associate with
Smad4 (Kretzschmar et al. 1997a
). Because Smad4 is required for signal
transduction by diverse SMAD pathways, it was possible that the
association with Smad4 might mediate nuclear translocation of
receptor-activated SMADs. Investigation of this question in the present
studies by use of the Smad4-deficient cell line SW480.7 clearly
indicates that Smad4 is not required for the nuclear translocation of
Smad1 or Smad2 in response to their respective agonists. Nuclear translocation of receptor-activated SMADs is clearly observed under
these conditions and is not further enhanced by transfection of Smad4.
Furthermore, a Smad4 construct containing an amino-terminal epitope tag
is cytoplasmic and remains in the cytoplasm upon BMP or TGF
stimulation when transfected alone. When cotransfected with
receptor-regulated SMADs, this Smad4 construct is translocated into the
nucleus. These results suggest that receptor-activated SMADs can
translocate into the nucleus independently of Smad4 and can take Smad4
into the nucleus after associating with it in the cytoplasm.
Formation of a ternary complex
Is Smad4 part of a transcriptional complex with receptor-regulated
SMADs? To address this question, we have reconstituted in mammalian
cells the FAST-1-dependent transcriptional response described by
Whitman and colleagues in Xenopus (Chen et al. 1996
). By use
of gel mobility shift assays, it was inferred previously that upon
activation by the receptor, Smad2 associates with FAST-1 in the nucleus
(Chen et al. 1996
). By transfecting FAST-1 and Smad2 into TGF
responsive lung epithelial cells, we provide evidence for this
interaction on the basis of coimmunoprecipitation of a
Smad2/FAST-1 complex. Using a panel of Smad2 and FAST-1
deletion mutants, we have determined that the C domains of the two
proteins mediate this interaction. In FAST-1, this Smad2-binding domain is separate from the previously identified DNA-binding domain (Chen et
al. 1996
). In Smad2, the C domain is also involved in the formation of
homo-oligomers and in the interaction with Smad4 (Hata et al. 1997
; Wu
et al. 1997
). The C domain is highly conserved among SMADs and its
tertiary structure is known in Smad4 (Shi et al. 1997
). The structure
of the Smad4 C domain has several solvent-exposed regions that are
conserved in Smad2 and may be involved in interactions with other
proteins. One of these proteins, in the case of Smad2, may be FAST-1.
Formation of the Smad2/FAST-1 complex in response to
TGF
does not require Smad4 and is not enhanced by overexpression
of Smad4, as determined in Smad4-deficient cells. When Smad4 is
present, however, it forms a ternary complex with Smad2 and FAST-1, as determined by coimmunoprecipitation of the three proteins. The interaction of Smad4 with FAST-1 requires Smad2. The evidence, therefore, suggests that upon phosphorylation by the TGF
receptor, Smad2 associates with Smad4 forming a complex that moves into the
nucleus where it binds FAST-1. Recently, Chen et al. (1997)
also
observed that Smad4 is in a complex with FAST-1 and Smad2 from injected
Xenopus embryos.
Interaction with DNA: Involvement of the Smad4 N domain
Our gel mobility shift assays and A3CAT reporter gene assays
indicate that formation of the
Smad2/Smad4/FAST-1 complex is essential for
optimal binding to the ARE and transcriptional activation of A3CAT. The
DNA-bound complex detected in the presence of Smad2, Smad4, and FAST-1
contains these three proteins, as determined by gel mobility supershift
assays with the appropriate antibodies. Little or no TGF
-inducible
ARE-binding complex or A3CAT activation were observed in cells
expressing Smad2 and FAST-1 but devoid of Smad4. Smad4 is therefore
required for optimal binding of the ternary complex to the ARE.
Previous work has shown that the C domain of Smad4 is sufficient for an
interaction with receptor-activated Smad2 (Hata et al. 1997
). The
present results, however, indicate that the C domain of Smad4 is not
sufficient to promote binding to the ARE and activation of A3CAT. The
amino-terminal region of Smad4 is required for optimal binding of the
ternary complex to DNA. The inability of the Smad4 C domain to activate
transcription in SW480.7 cells was observed not only with the A3CAT
reporter but also with the TGF
-responsive p3TP-luciferase
reporter (F. Liu et al., unpubl.). A previous study showed that
transfection of a Smad4 C domain can lead to transcriptional activation
of p3TP-luciferase in R1B/L17 cells that contain
wild-type of Smad4 (Hata et al. 1997
). It should be noted that these
results are not incompatible because the Smad4 C domain could act in
R-1B/L17 cells by associating with the endogenous Smad4.
The mechanism by which Smad4 promotes interaction of the ternary
complex with DNA remains to be elucidated. FAST-1 can bind to ARE
directly in yeast (Chen et al. 1996
), and FAST-1/ARE
complexes have been detected with whole cell extracts from
FAST-1-transfected cells (Chen et al. 1996
; F. Liu et al., unpubl.).
Therefore, Smad4 might act by enhancing the intrinsic DNA-binding
activity of FAST-1 in the ternary complex. Although Smad4 does not
appear to stabilize the interaction between FAST-1 and Smad2 in
solution, we cannot exclude the possibility that the Smad4 N domain
stabilizes the interaction between FAST-1 and Smad2 on DNA.
Alternatively, one attractive possibility is that the Smad4 N domain
has affinity for DNA. This possibility is supported by the recent
observation that the homologous amino-terminal region of
Drosophila Mad can bind directly to a specific DNA sequence in
the promoter of the Dpp target gene vestigial (Kim et al.
1997
). Although we were unable to detect DNA binding by Smad4 alone,
this could be as a result of a low affinity of Smad4 for DNA. Smad4
might contact DNA only after being recruited into the ternary complex
with Smad2 and FAST-1. These possibilities warrant further
investigation.
The Smad4 N domain has been shown to inhibit the ability of the C
domain to associate with Smad2 (Hata et al. 1997
). The Smad4 N domain,
however, has been shown recently to enhance agonist-dependent signaling
(de Caestecker et al. 1997
). In light of this and the present results,
it is possible that Smad4 N and C domains interact with each other in
the basal state in a reciprocally inhibitory fashion.
Trancriptional activation requiring the Smad4 C domain
If the DNA-binding requirement of a SMAD complex is bypassed, is
Smad4 still required for transcriptional activation? We investigated this question by fusing the GAL4 DNA-binding domain to receptor regulated SMADs to provide DNA-binding activity independent of FAST-1
or other cofactors. In cells containing endogenous Smad4, these
GAL4-Smad1 and GAL4-Smad2 fusions can mediate agonist-dependent activation of a GAL4 reporter gene (Liu et al. 1996
; Hayashi et al.
1997
). In Smad4 deficient SW480.7 cells, however, these constructs are
inactive and do not mediate transcriptional activation in response to
BMP4 or TGF
. Transcriptional activation under these conditions is
rescued by cotransfection of full-length Smad4 and, importantly, by
cotransfection of the Smad4 C domain. Thus, when the DNA-binding
function is supplied by an ectopic DNA-binding domain,
receptor-activated SMADs still require Smad4 for transcriptional activation. In this case, the C domain of Smad4 is sufficient to
provide this rate-limiting function. It is possible that the Smad4 C
domain, either alone or jointly with the associated C domain of Smads 1 or 2, activates basal transcription machinery.
In conclusion, the present results shed light on the role of Smad4 in
the SMAD-signaling pathway. Collectively, the evidence suggests a model
(Fig. 8) in which a receptor-regulated SMAD, such as
Smad1 or Smad2, moves into the nucleus where it can associate with a
sequence-specific DNA-binding protein such as FAST-1 without requiring
Smad4. Association of Smad2 with Smad4, however, presumably in the
cytoplasm, and formation of a ternary complex with FAST-1 in the
nucleus are required for optimal binding of this complex to DNA and for
transcriptional activation. The contributions to DNA binding and
transcriptional activation appear to be made through distinct regions
of Smad4. The dual function of Smad4 in transcriptional regulation
highlights its central role in TGF
signaling.
|
| |
Materials and methods |
|---|
|
|
|---|
Constructs
Smad2 cDNA (GenBank accession no. AF027964) was obtained by
sequencing and ligation of human EST cDNA clones. GAL4-Smad2 was
constructed by inserting the human Smad2 cDNA into the pSG424 vector
(Sadowski and Ptashne 1989
). Smad3 cDNA and the various Myc tagged
FAST-1 derivatives were constructed in the CS2 vector (Turner and
Weintraub 1994
). All other constructs have been described (Liu et al.
1996
; Hata et al. 1997
; Kretzschmar et al. 1997a
).
Immunofluorescence
SW480.7 cells were transfected with lipofectin reagent (GIBCO
BRL) for 20 hr and then plated into chamber slides. BMP or TGF
stimulation was provided by cotransfecting the activated BMP type I
receptor, BMPR-IA(Q233D) (Hoodless et al. 1996
) or the activated TGF
type I receptor, T
R-I(T204D) (Wieser et al. 1995
), and
incubated with 2 nM BMP4 or 1 nM TGF
1 for 1 hr. Cells were then fixed by methanol/acetone.
Immunostaining was performed by incubation with the M2 Flag antibody
(Eastman Kodak) at 1 µg/ml for 1 hr followed by
incubation with the FITC-conjugated goat anti-mouse antibody (1 : 100) (Jackson Immunologicals) for 1 hr.
Immunoprecipitation and immunoblot assay
R1B/L17 and COS cells were transfected with
DEAE-dextran, and SW480.7 cells were transfected with lipofectin.
Cells were induced with 500 pM TGF
1 for 1 hr and then
lysed in 1 ml of TNE buffer [10 mM Tris (pH 7.8), 150 mM NaCl, 1 mM EDTA, 1% NP-40] in the presence of
protease inhibitors. Immunoprecipitation was performed by incubation
with the M2 Flag monoclonal antibody (Eastman Kodak) or with 9E10 Myc
monoclonal antibody (Santa Cruz Biotechnology) for 1 hr.
Immunoprecipitates were separated in an 8% SDS-PAGE (except for Fig.
3B, in a 14% SDS-PAGE) and transferred to a PVDF membrane.
Immunoblotting was performed by use of antibodies against the epitopes
Flag, Myc, or HA (12CA5 antibody, Boehringer Mannheim), followed by
incubation with the HRP-conjugated goat anti-mouse antibody and
detected by chemiluminescence (Amersham).
To detect the ternary complex, transfected COS cells were lysed in 1 ml of TNE buffer and immunoprecipitated with agarose-coupled M2 Flag antibody for 3.5 hr. The precipitates were eluted twice with 250 µg/ml of Flag peptide (Eastman Kodak) and the eluate diluted with 0.8 ml of TNE buffer, immunoprecipitated with anti-Myc antibody for 6 hr, and subjected to anti-HA immunoblotting.
Gel mobility shift and supershift assay
SW480.7 cells were transfected with lipofectin and treated with
TGF
for 18 hr. Nuclear extracts were prepared by resuspending cells in a hypotonic buffer containing 10% glycerol, 20 mM
HEPES (pH 7.9), 0.1 mM EDTA, 50 mM KCl, 2 mM DTT, 0.15 mM spermine, 0.5 mM
spermidine, and protease and phosphatase inhibitors. Cell suspensions
were frozen in liquid nitrogen and then thawed on ice. The nuclei
fraction was recovered by centrifugation and then incubated on ice with
a hypertonic buffer containing 20% glycerol, 20 mM HEPES (pH
7.9), 0.1 mM EDTA, 600 mM KCl, and 2 mM
DTT with protease and phosphatase inhibitors. After centrifugation, the supernatant was recovered as nuclear extract. Whole cell extract was
prepared by freezing cell pellet in liquid nitrogen and lysis of the
frozen cell pellet in a buffer containing 10 mM HEPES (pH 7.9), 300 mM NaCl, 0.1 mM EGTA, 20% glycerol, and
0.2% NP-40 with protease inhibitors and phosphatase inhibitors.
DNA-binding assays were performed essentially as described (Huang et
al. 1995
) with 1 ng of radiolabeled ARE probe. For antibody supershift
assays, extracts were incubated for 10 min in binding buffer, then 15 min with the probe, and 10 min with antibodies. DNA-protein complexes were resolved on a 4% (40 : 1) polyacrylamide gels containing 1%
glycerol.
CAT assays
SW480.7 cells or R1B/L17 cells were transfected
with DEAE-dextran and treated with 2 nM BMP4 (Genetics
Institute), 2.5 nM activin A (National Hormone and Pituitary
Program, National Institute of Diabetes and Digestive Kidney Diseases),
or 500 pM TGF
1 (R&D Systems) for 18-22 hr. CAT activity
was quantitated by scintillation counting or PhosphorImager analysis.
| |
Acknowledgments |
|---|
We gratefully acknowledge M. Whitman for the FAST-1 cDNA and the A3CAT reporter gene, Y. Zhang and R. Derynck for the Smad3 cDNA, H. Ge, C. Fasching, and E. Stanbridge for SW480.7 cells, Genetics Institute for BMP4, the National Hormone and Pituitary Program for activin, K. Manova for assistance with cell imaging, A. Hata and R.S. Lo for constructs, and J. Doody, R.S. Lo, D. Wotton, Y.G. Shi, C. Zhang, and Y.-G. Chen for helpful discussions and assistance. This work was supported by grants from the National Institutes of Health to J.M. and to the Memorial Sloan-Kettering Cancer Center. F.L. and C.P. are recipients of postdoctoral fellowships from the Jane Coffin Childs Memorial Fund for Medical Research and the International Agency for Research on Cancer, respectively. J.M. is an investigator of the Howard Hughes Medical Institute.
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
| |
Footnotes |
|---|
Received August 29, 1997; revised version accepted October 3, 1997.
1 Corresponding author.
E-MAIL j-massague{at}ski.mskcc.org; FAX (212) 717-3298.
| |
References |
|---|
|
|
|---|
and activin.
Mol. Cell Biol.
14:
3810-3821
signaling.
Nature
383:
691-696[CrossRef][Medline].
responsive elements in WAF1/Cip1/p21 promoter.
J. Biol. Chem.
270:
28623-28628
-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.
Cell
86:
543-552[CrossRef][Medline].
superfamily.
Cell
85:
479-487[CrossRef][Medline].
-induced cell cycle arrest.
Nature
371:
257-261[CrossRef][Medline].
receptor and functions as an antagonist of TGF
signaling.
Cell
89:
1165-1173[CrossRef][Medline].
in cells lacking the CDK inhibitor p15.
Nature
387:
417-422[CrossRef][Medline].
stimulates a2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site.
J. Biol. Chem.
269:
14828-14834
.
J. Biol. Chem.
266:
23048-23052
1 and cAMP inhibit transcription of epidermal growth factor- and oncogene-induced transin RNA.
J. Biol. Chem.
263:
16999-17005
mediator Smad1 is directly phosphorylated and functionally activated by the BMP receptor kinase.
Genes & Dev.
11:
984-995
family mediator Smad1.
Nature
389:
618-622[CrossRef][Medline].
signaling pathways.
Nature
383:
832-836[CrossRef][Medline].
signal transduction by human bsp-1.
J. Biol. Chem.
271:
17617-17620
receptor and phosphorylation is required for nuclear accumulation and signaling.
Cell
87:
1215-1224[CrossRef][Medline].
signaling through the Smad pathway.
Trends Cell Biol.
7:
187-192.
signaling pathway.
J. Biol. Chem.
272:
2896-2900
receptor-mediated signaling through Smad2, Smad3 and Smad4.
EMBO J.
16:
5353-5362[CrossRef][Medline].
responsive cells.
Development
122:
2099-2108[Abstract].
1 Inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming protein with pRB binding domains.
Cell
61:
777-785[CrossRef][Medline].
.
Genes & Dev.
9:
1831-1845
.
Cell
5:
405-414.
pathway components.
Proc. Natl. Acad. Sci.
93:
790-794